A leading geneticist recounts the story of one rogue scientist, and the damage he caused. ‘He should be stopped from doing anything like this again,’ says Robin Lovell-Badge
Some medicines may carry a higher risk of side effects for the lungs than previously thought, IMI research reveals. The drugs studied work well for most, but doctors should monitor patients for side effects.
Spain is widely regarded as having one of the world’s best healthcare systems. Can a series of experiments in ‘value-based’ care help to make it even better? A new Science|Business report finds out
In a new series of videos released during IMI’s 10th anniversary, IMI project participants from universities, patient groups, SMEs and the pharmaceutical industry explain how they are benefiting from participating in IMI projects and how they think IMI is changing medical research.
In a new series of videos released during IMI’s 10th anniversary, IMI project participants from universities, patient groups, SMEs and the pharmaceutical industry explain how they are benefiting from participating in IMI projects and how they think IMI is changing medical research.
The EU’s outgoing health chief reflects on three decades in Brussels and how life has got steadily better. But he worries citizens are now forgetting the benefits of science. That could threaten recent medical advances, he says
The eTOX project developed innovative strategies and novel software tools to better predict the safety and side effects of new candidate medicines for patients. In an interview, the project leaders explain how the tools developed by the project are already helping pharmaceutical companies make better-informed decisions in their pursuit of developing safer drugs for patients.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.